Discovery is major step towards a stem cell replacement therapy for Duchenne Muscular Dystrophy
UCLA scientists have developed a new strategy to efficiently isolate, mature and transplant skeletal muscle cells created from human pluripotent stem cells, which can produce all cell types of the body. The findings are a major step towards developing a stem cell replacement therapy for muscle diseases including Duchenne Muscular Dystrophy, which affects approximately 1 in 5,000 boys in the U.S. and is the most common fatal childhood genetic disease.
The study was published in the journal Nature Cell Biology by senior author April Pyle, associate professor of microbiology, immunology and molecular genetics and member of the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA. Using the natural human development process as a guide, the researchers developed ways to mature muscle cells in the laboratory to create muscle fibers that restore dystrophin, the protein that is missing in the muscles of boys with Duchenne.
Without dystrophin, muscles degenerate and become progressively weaker. Duchenne symptoms usually begin in early childhood; patients gradually lose mobility and typically die from heart or respiratory failure around age 20. There is currently no way to reverse or cure the disease.
For years, scientists have been trying different methods that direct human pluripotent stem cells to generate skeletal muscle stem cells that can function appropriately in living muscle and regenerate dystrophin-producing muscle fibers. However, the study led by Pyle found that the current methods are inefficient; they produce immature cells that are not appropriate for modeling Duchenne in the laboratory or creating a cell replacement therapy for the disease.
“We have found that just because a skeletal muscle cell produced in the lab expresses muscle markers, doesn’t mean it is fully functional,” said Pyle. “For a stem cell therapy for Duchenne to move forward, we must have a better understanding of the cells we are generating from human pluripotent stem cells compared to the muscle stem cells found naturally in the human body and during the development process.”
By analyzing human development, the researchers found a fetal skeletal muscle cell that is extraordinarily regenerative. Upon further analysis of these fetal muscle cells two new cell surface markers called ERBB3 and NGFR were discovered; this enabled the reserchers to precisely isolate muscle cells from human tissue and separate them from various cell types created using human pluripotent stem cells.
Once they were able to isolate skeletal muscle cells using the newly identified surface markers, the research team matured those cells in the lab to create dystrophin-producing muscle fibers. The muscle fibers they created were uniformily muscle cells, but the fibers were still smaller than those found in real human muscle.
“We were missing another key component,” said Michael Hicks, lead author of the study. The skeletal muscle cells were not maturing properly, he explained. “We needed bigger, stronger muscle that also had the ability to contract.”
Once again, the team looked to the natural stages of human development for answers. Hicks discovered that a specific cell signaling pathway called TGF Beta needs to be turned off to enable generation of skeletal muscle fibers that contain the proteins that help muscles contract. Finally, the team tested their new method in a mouse model of Duchenne.
“Our long term goal is to develop a personalized cell replacement therapy using a patient’s own cells to treat boys with Duchenne,” said Hicks. “So, for this study we followed the same steps, from start to finish, that we’d follow when creating these cells for a human patient.”
First, the Duchenne patient cells were reprogrammed to become pluripotent stem cells. The researchers then removed the genetic mutation that causes Duchenne using the gene editing technology CRISPR-Cas9. Using the ERBB3 and NGFR surface markers, the skeletal muscle cells were isolated and then injected into mice at the same time a TGF Beta inhibitor was administered.
“The results were exactly what we’d hoped for,” said Pyle. “This is the first study to demonstrate that functional muscle cells can be created in a laboratory and restore dystrophin in animal models of Duchenne using the human development process as a guide.”
Further research will focus on generating skeletal muscle stem cells that can respond to continuous injury and regenerate new muscle long-term using the team’s new isolation and maturation strategy.
The Latest on: Duchenne Muscular Dystrophy
- Bio Roundup: Seres Soars, MesoBlast Vote, Duchenne Decision & Moreon August 14, 2020 at 6:54 am
The road of drug development is rife with detours and disappointments but Seres Therapeutics showed this week that course corrections can work. Four years ...
- Duchenne Muscular Dystrophy Market 2020 : Top Countries Data, Market Size with Global Demand Analysis and Business Opportunities Outlook 2026on August 14, 2020 at 1:26 am
Research Reports Recently published a detailed market research study titled “GlobalDuchenne Muscular Dystrophy Market2020 by Manufacturers, Types (Deflazacort, Prednisone, Others), Applications (Male, ...
- Drug Granted Accelerated Approval for Rare Duchenne Muscular Dystrophy Mutationon August 13, 2020 at 9:47 pm
Accelerated approval has been granted to Viltepso (viltolarsen) injection for treatment of patients with Duchenne muscular dystrophy (DMD) and a mutation of the DMD gene amenable to exon 53 skipping, ...
- With FDA Nod, NS Pharma Duchenne Drug Becomes Sarepta Competitoron August 12, 2020 at 7:44 pm
Duchenne muscular dystrophy (DMD) patients whose disease is characterized by a particular genetic mutation now have a new treatment option following the ...
- FDA OK NS Pharma's viltolarsen for certain Duchenne patientson August 12, 2020 at 5:24 pm
Ltd. (OTC:NPNKF) unit NS Pharma announces the accelerated FDA nod for Viltepso (viltolarsen) for the treatment of patients with Duchenne muscular dystrophy (DMD) amenable to exon 53 skipping, a ...
- FDA approves new treatment option for patients with rare Duchenne muscular dystrophy mutationon August 12, 2020 at 4:13 pm
Today, the U.S. Food and Drug Administration granted accelerated approval to Viltepso (viltolarsen) injection for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed ...
- Rare Duchenne Muscular Dystrophy Mutation Has New Txon August 12, 2020 at 1:47 pm
"The FDA is committed to fostering drug development for serious neurological disorders like Duchenne muscular dystrophy," Billy Dunn, MD, director of the Office of Neuroscience in the FDA's Center for ...
- FDA Approves Targeted Treatment for Rare Duchenne Muscular Dystrophy Mutationon August 12, 2020 at 1:04 pm
FDA has granted accelerated approval to an injection for the treatment of Duchenne muscular dystrophy in patients.
- Epirium Bio Announces Commencement of Phase 1 Clinical Trial of EPM-01 in Becker Muscular Dystrophyon August 12, 2020 at 6:14 am
Epirium Bio Inc., a clinical-stage biopharmaceutical company pursuing novel and clinically significant therapeutic approaches for neuromuscular, neurodegenerative and mitochondrial disorders, today an ...
- FibroGen Announces First Patient Enrolled in Pamrevlumab Phase 3 Clinical Trial in Patients with Duchenne Muscular Dystrophyon August 11, 2020 at 4:20 am
FibroGen, Inc. (NASDAQ: FGEN) announced the initiation of LELANTOS, a Phase 3, randomized, double-blind, placebo-controlled trial of pamrevlumab or placebo in combination with systemic corticosteroids ...
via Google News and Bing News